"Dissolved virus immunity and checkpoint suppression"! Oncorus has partnered with Mercato to develop ONCR-177/Keytruda for the treatment of a wide range of solid tumors!

July 19, 2020 /PRNewswire/ -- Oncorus is a pharmaceutical company dedicated to the development of next-generation viral immunotherapyRecently, the company entered into a clinical trial cooperation agreement with Merck and Co to evaluate ONCR-177 and anti-PD-1 therapy Keytruda (Corrida, generic name: pembrolizumab, Pabolizhu monotomalysis) as part of an ongoing phase I study to treat patients with advanced and/or recurrent skin, epithelial or metastatic lymph node sylicosisThis Phase I study is an open-label, multi-center, dose-increasing, and extended trial that will assess safety and tolerance and determine the recommended Phase II dose, as well as the initial anti-tumor activity of NCR-177 monotherapy and combination with KeytrudaAfter determining the recommended phase II dose, the study will send patients into a heliological-specific extended queue to demonstrate the safety and efficacy of ONCR-177 as a monotherapy and combination with Keytruda, in addition to biomarker stagdoglate explorationThe extended queue will be in groups of patients with physical tumors that are difficult to treat, ineligible, relapsed and/or intolerant, or without standard care, including breast cancer, head and neck squamous cell carcinoma (SCCHN), and melanomaONCR-177 is a leading candidate for Oncorus and is developing a multi-body tumor indication, a viral immunotherapy for intra-tumor injection, developed using Oncorus's proprietary tumor-soluble herpes simplex virus (oHSV) platform to increase effectiveness without sacrificing safety, a challenge for these early projectsONCR-177 combines six immunothologist methods, including oHSV and 5 immunostimulation factors of genetic ally (IL-12, CCL4, FLT3LG, anti-PD-1, anti-CTLA-4), designed to launch a powerful, multi-dimensional attack on cancerThe mechanisms of action between ONCR-177 and Keytruda are considered highly complementaryKeytruda activates T cells by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2ONCR-177 is designed to induce death of immunogenic cancer cells and stimulate T cells and other key cells in the congenital and adaptive immune system to drive a long-lasting systemic antitumor responseApplying these two methods together has the potential to enhance anti-tumor immunity, form anti-tumor immune memory, and help more patients become responders to immunotherapyIn addition to tumor activity, ONCR-177 contains 5 immuno-irritating transgenics (IL-12, CCL4, FLT3LG, anti-PD-1, anti-CTLA-4)THE ONCR-177 REPRESENTS A GREATER EFFECTIVE LOAD CAPACITY THAN OTHER VIRAL IMMUNOTHETHERS THAT ARE CURRENTLY APPROVED OR CLINICALLY DEVELOPEDIn preclinical studies, ONCR-177 has been shown to stimulate multiple branches of the immune system, drive the far-off effect (abscopal activity) and extend survival, while limiting systemic exposure of genetically modified products such as IL-12, which cannot be used systematically and safely due to toxic effectsTHE ONCR-177 ALSO RETAINS FULL REPLICATION CAPABILITY TO EFFECTIVELY KILL TUMOR CELLS, AND USES TWO HIGHLY INNOVATIVE METHODS - USING MICRORNA TARGET SEQUENCES AND A PATENTED MUTATION DESIGNED IN THE HSV-1 PROTEIN UL37 - WHICH ALLOWS TUMOR-SPECIFIC REPLICATION, LIMITING VIRAL ACTIVITY TO TUMOR CELLS WITHOUT HARMING NORMAL TISSUE() Original source: Oncorus Announces Clinical Trial Collaboration with Merck to The Combination of Oncorus' ONCR-177 with Merck's KEYTRUDa (pembrolizumab) in Patients with Advanced and or Refractory Cutan, Subcutor d'Oreal.